Co-Diagnostics Inc（CODX）资讯与事件CODXCo-Diagnostics Inc

Selling Stockholders Plan to Sell 3.4M Shares of Common Stock

This filing relates to the offer and sale from time to time by the selling stockholders of up to 3.4M shares of common stock. The company is not selling any shares under this prospectus and will not receive any of the proceeds from the sale of shares by the selling stockholders.

Co-Diagnostics Submits Dual 510(k) Application to FDA

Co-Diagnostics announced that it has submitted a Dual 510(k) premarket notification, with a concurrent CLIA Waiver by Application, to the U.S. FDA for the Co-Dx PCR Flu A/B & RSV upper respiratory multiplex test on the Co-Dx PCR Pro instrument. The submission follows the company's previously announced completion of the clinical and analytical performance studies supporting the test.

Co-Diagnostics and CoSara Complete Ebola Test Proof of Concept

Co-Diagnostics announced that CoSara Diagnostics, the company's joint venture in India, has sent test kits of the Saragene Bundibugyo Virus Test to a third-party laboratory for evaluation following a request by the India Centre for Cellular and Molecular Platforms, an initiative supported by the India Department of Biotechnology. The company also announced successful completion of a proof-of-concept study evaluating an extraction-free Co-Primers Ebola test on the Co-Dx PCR Pro instrument using diluted plasma as a sample type. This feasibility work represents the first blood-borne assay designed for use on the PCR Pro point-of-care instrument. The analytical studies were initiated following a request by C-CAMP for 200 of CoSara's Bundibugyo tests.